Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans

Drug Metabolism and Disposition

Volumn 36, Issue 5, 2008, Pages 851-862

  Klieber, Sylvie ^a   Hugla, Sébastien ^a   Ngo, Robert ^a   Arabeyre Fabre, Catherine ^a   Meunier, Viviane ^a   Sadoun, Freddy ^a   Fedeli, Olivier ^a   Rival, Martine ^a   Bourrie, Martine ^a   Guillou, François ^a   Maurel, Patrick ^b   Fabre, Gérard ^a  

^a SANOFI   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYMIDAZOLAM; ALPHA HYDROXYMIDAZOLAM; DRUG METABOLITE; GLUCURONIC ACID; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A4; KETOCONAZOLE; MIDAZOLAM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CONFORMATION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME KINETICS; FEMALE; GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOMERISM; LIVER MICROSOME; MALE; METABOLIC CLEARANCE RATE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ADULT; AGED; CELLS, CULTURED; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HEPATOCYTES; HUMANS; KETOCONAZOLE; MALE; MICROSOMES, LIVER; MIDAZOLAM; MIDDLE AGED;

EID: 42449095963     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.019539     Document Type: Article

References (42)

1. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832.
2. Bourrié M, Meunier V, Berger Y, and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
3. Campos MPA, Bergter L, De Paula e Silva CHT, and Seidl PR (1999) Internal rotation process in endo-cis-N-(o-tolyl)bicyclo[2.2.1]heptene-2.3-dicarboximide and its oxidation products. Magn Reson Chem 37:317-321.
4. Chung E, Nafziger AN, Kazierad DJ, and Bertino JS Jr (2006) Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther 79:350-361.
5. Dundee JW, Halliday NJ, Harper KW, and Brogden RN (1984) Midazolam. A review of its pharmacological properties and therapeutic use. Drugs 28:519-543.
6. Ehmer U, Vogel A, Schutte JK, Krone B, Manns MP, and Strassburg CP (2004) Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 39:970-977.
7. Fabre G, Crevat-Pisano P, Dragna S, Covo J, Barra Y, and Cano JP (1988a) Involvement of the macrolide antibiotic inducible cytochrome P-450 LM3c in the metabolism of midazolam by microsomal fractions prepared from rabbit liver. Biochem Pharmacol 37:1947-1953.
8. Fabre G, Rahmani R, Placidi M, Combalbert J, Covo J, Cano JP, Coulange C, Ducros M, and Rampal M (1988b) Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. Biochem Pharmacol 37:4389-4397.
9. Galetin A, Ito K, Hallifax D, and Houston JB (2005) CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 314:180-190.
10. Gascon MP and Dayer P (1991) In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 41:573-578.
11. Ghosal A, Satoh H, Thomas PE, Bush E, and Moore D (1996) Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. Drug Metab Dispos 24:940-947.
12. Gorski JC, Hall SD, Jones DR, VandenBranden M, and Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653.
13. Guengerich FP (1995) Human cytochrome P450 enzymes, in Cytochrome P450 (Ortiz de Montellano PR ed) pp 473-535, Plenum Press, New York.
14. Heizmann P and Ziegler WH (1981) Excretion and metabolism of 14C-midazolam in humans following oral dosing. Arzneimittel-Forschung 31:2220-2223.
15. Hosea NA, Miller GP, and Guengerich FP (2000) Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39:5929-5939.
16. Ismail IM, Dear GJ, Roberts AD, Plumb RS, Ayrton J, Sweatman BC, and Bowers GD (2002) N-O glucuronidation: a major human metabolic pathway in the elimination of two novel anti-convulsant drug candidates. Xenobiotica 32:29-43.
17. Isom HC and Georgoff I (1984) Quantitative assay for albumin-producing liver cells after simian virus 40 transformation of rat hepatocytes maintained in chemically defined medium. Proc Natl Acad Sci U S A 81:6378-6382.
18. Kemp DC, Fan PW, and Stevens JC (2002) Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694-700.
19. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, and Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96.
20. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
21. Lam Y, Alfaro C, Ereshefsky L, and Miller M (2003) Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol 43:1274-1282.
22. Lam Y, Ereshefsky L, Alfaro C, and Miller M (1999) In vivo inhibition of midazolam disposition by ketoconazole and fluoxetine, and comparison to in vitro prediction. Clin Pharmacol Ther 65:143.
23. Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, and Frye RF (2002) Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 72:718-728.
24. Mäenpää J, Hall SD, and Ring BJ (1998) Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphtoflavone, terfenadine and testosterone. Pharmacogenetics 8:137-155.
25. Miners JO and Mackenzie PI (1991) Drug glucuronidation in humans. Pharmacol Ther 51:347-369.
26. Olkkola KT, Backman JT, and Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485.
27. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
28. Pollard HB, Menard R, Brandt HA, Pazoles CJ, Creutz CE, and Ramu A (1978) Application of Bradford's protein assay to adrenal gland subcellular fractions. Anal Biochem 86:761-763.
29. Reves JG, Fragen RJ, Vinik HR, and Greenblatt DJ (1985) Midazolam: pharmacology and uses. Anesthesiology 62:310-324.
30. Satoh T, Tomikawa Y, Takanashi K, Itoh S, and Yoshizawa I (2004) Studies on the interaction between drugs and estrogen. III. Inhibitory effects of 29 drugs reported to induce gynecomastia on the glucuronidation of estradiol. Biol Pharm Bull 27:1844 -1849.
31. Schantl JG (1995) Synthetic, structural, reactive and biological aspects of novel tetraazabicyclooctanes. Farmaco 50:379-394.
32. Siddle DW, Faithfull L, Gleave M, Wright P, Lindsay N, and Khol C (2003) Midazolam is metabolized by UGT1A4 in human hepatocytes and hepatic microsomes. Drug Metab Rev 35:55.
33. 1H NMR study. Indian J Chem 32B:1143-1148.
34. Takeda S, Kitajima Y, Ishii Y, Nishimura Y, Mackenzie PI, Oguri K, and Yamada H (2006) Inhibition of UDP-glucuronosyltransferase 2B7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. Drug Metab Dispos 34:1277-1282.
35. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
36. Tsunoda SM, Velez RL, and Greenblatt DJ (1999) Ketoconazole (K) inhibition of intestinal and hepatic cytochrome P450 3A4 (CYP3A4) activity using midazolam (M) as an in vivo probe. Clin Pharmacol Ther 65:172.
37. Voitenko ZV, Pokholenko AA, Shkarov OO, Kovtunenko VA, and Babichev FS (2002) Cycloaddition in condensed isoindoles. 2*. Method for obtaining new derivatives of 2-phenylpyridine. Chem Heter Comp 38:190-196.
38. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, and Shader RI (1996) Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 36:783-791.
39. Wang RW, Newton DJ, Liu N, Atkins WM, and Lu AYH (2000) Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28:360-366.
40. Wrighton SA and Ring BJ (1994) Inhibition of human CYP3A catalyzed 1′-hydroxymidazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm Res 11:921-924.
41. Yong WP, Ramirez J, Innocenti F, and Ratain MJ (2005) Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin Cancer Res 11:6699-6704.
42. Zhu B, Bush D, Doss GA, Vincent S, Franklin RB, and Xu S (2008) Characterization of 1′-hydroxymidazolam glucuronidation in human liver microsomes. Drug Metab Dispos 36:331-338.